Figure 3

Kaplan-Meier metastasis-free survival curves for ER+/HER2− breast cancers. (A) Curves representing EndoPredict (EP) test results indicating estimated high and low risk of metastasis-free survival (MFS). The cutoff point for EP score–based risk stratification was prespecified at 5. For the premenopausal patients, MFS in the EP score–based low-risk category was 93% vs 67% in the EP score–based high-risk group. For the postmenopausal patients, MFS in the EP score–based low-risk category was 92% vs 74% in the EP score–based high-risk group. (B) Curves representing results based on the combined molecular and clinical EPclin indicating estimated high and low risk of MFS. The cutoff point for EPclin score–based risk stratification was prespecified at 3.3. In the EPclin premenopausal patients, MFS in the EPclin score–based low-risk group was 100% vs 70% in the EPclin score–based high-risk category. In the postmenopausal patients, MFS in the EPclin score–based low-risk category was 100% vs 76% in the EPclin score–based high-risk group. The samples included 300 premenopausal patients and 255 postmenopausal patients. Numbers in parentheses indicate the 95% confidence intervals of the hazard ratios. ARR: Absolute risk reduction estimated at 10 years.